SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

RBC Raises Kymera Therapeutics Price Target to $116

RBC raised its price target on Kymera Therapeutics to $116 from $112 and maintained a Sector Perform rating with speculative risk.

KYMR

Related stories